title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Eligibility to provide sputum samples (S3, or S3 and S4) for culture testing | Collection of sputum samples for culture testing, and the number of samples requested, differed between the first 4 study communities (in which an “intensive diagnostic phase” (IDP) was conducted) and the remaining 17 “non-IDP” communities.In the 4 IDP communities, all sputum-eligible individuals who returned on “day 2... | PMC10490889 | ||
Culture testing of sputum samples | TB | All sputum samples that were collected for culture testing were batched and kept in a refrigerator until being transported on the same day to the central laboratory in a cooler box. In Zambia, samples were taken to the Zambart central laboratory in Lusaka, and in South Africa to the National Health Laboratory Service (... | PMC10490889 | |
Definition of the primary outcome of prevalent TB | TB | Sputum-eligible participants who had valid Xpert-Ultra results from both S1 and S2 and were not culture-eligible (according to the non-IDP community definition) were classified as prevalent TB (yes or no) based solely on their Xpert-Ultra results (see above).Sputum-eligible participants who were culture-eligible (accor... | PMC10490889 | |
Data capture and statistical analysis | TB | Data were captured digitally into an electronic data management system (DMS) specifically designed for the TREATS TB prevalence survey while culture data were captured using each laboratory’s existing laboratory information management system (LIMS).For sputum-eligible participants whose prevalent TB status could not be... | PMC10490889 | |
Results | PMC10490889 | |||
Enumeration and participation | A total of 122,381 household members (all ages) were enumerated, 89,850 in Zambia and 32,531 in South Africa, 83,092 were eligible to participate, and 49,556 (59.6%) participated (Figs | PMC10490889 | ||
Flow diagram by trial arm of participant enrolment, sample collection, and MTB detection. | MTB, | PMC10490889 | ||
Characteristics of participants | The age-sex profile of participants was similar by trial arm ( | PMC10490889 | ||
Provision of sputum samples, valid Xpert-Ultra results, culture eligibility, and valid culture results | Around 93% of sputum-eligible individuals (7,502/8,083) produced at least 1 sputum sample for Xpert-Ultra testing, 91% provided 2 samples (S1 and S2), and 88% (7,138/8,083) had valid Xpert-Ultra results from both sputum samples, among whom 4.3% (308/7,138) were culture-eligible ( | PMC10490889 | ||
TB prevalence estimates and comparison among trial arms | TB | Overall, the estimated proportion of survey participants with prevalent TB (after imputing missing data) was 0.92% (457/49,556), lower in Zambian (0.51%, 158/30,908) than South African communities (1.60%, 299/18,648). TB prevalence estimates varied substantially among communities ( | PMC10490889 | |
TB prevalence estimates, by country and HIV status | TB | TB prevalence was higher among HIV–positive than HIV–negative individuals across almost all combinations of country, sex, and age group ( | PMC10490889 | |
Sensitivity analyses | Findings about trial arm comparisons were similar in sensitivity analyses ( | PMC10490889 | ||
Discussion | PMC10490889 | |||
Key findings | TB | We found no evidence that the PopART intervention reduced TB prevalence through UTT for HIV and systematic symptom screening for TB, after 4 years of intervention delivery (2014 to 2017 inclusive) and with TB prevalence measured 2 to 4 years later in 2019 to 2021. This lack of evidence was found overall and also in sub... | PMC10490889 | |
Interpretation of findings and consistency with other studies | TB, infection | INFECTION | Several factors could have contributed to the lack of evidence for impact of the PopART intervention on TB prevalence. First, the TB-specific component of the PopART intervention consisted of systematic TB screening based on TB symptoms. National and subnational TB prevalence surveys have consistently found that a cons... | PMC10490889 |
Generalisability, strengths, and limitations | TB | The TREATS TB prevalence survey was large, including around 50,000 individuals, and covering 21 communities. Nevertheless, the study was only powered to detect fairly large reductions (of the order of 40% to 50%) in TB prevalence in the PopART intervention trial arms (arms A and B) compared with the standard-of-care ar... | PMC10490889 | |
Implications of study findings | TB | DISEASE | Our findings indicate that systematic screening for TB that is based on symptom screening alone is not sufficient to achieve a large reduction in TB prevalence over a period of several years. Including chest X-ray screening alongside TB symptom screening could substantially increase the sensitivity of systematic screen... | PMC10490889 |
Conclusions | TB | There was no evidence that the PopART intervention reduced TB prevalence. Potential explanations include: similarly high coverage of HIV testing and treatment in all trial arms by 2019 to 2021; systematic TB symptom screening missing subclinical TB; ART coverage affecting TB prevalence less than TB incidence; the initi... | PMC10490889 | |
Supporting information | PMC10490889 | |||
Sputum eligibility definition. | (TIF)Click here for additional data file. | PMC10490889 | ||
Culture eligibility algorithm based on the results of Xpert-Ultra testing on 2 sputum samples (S1 and S2). | (TIF)Click here for additional data file. | PMC10490889 | ||
Decision tree for culture eligibility and collection of S3 and S4 samples. | (TIF)Click here for additional data file. | PMC10490889 | ||
Algorithm to determine final culture result based on the culture results from each of 2 MGIT tubes. | (TIF)Click here for additional data file. | PMC10490889 | ||
Flow diagram by country of participant enrolment, sample collection, and MTB detection. | (TIF)Click here for additional data file. | PMC10490889 | ||
Flow diagram by 3 trial arms of participant enrolment, sample collection, and MTB detection. | (TIF)Click here for additional data file. | PMC10490889 | ||
Culture testing of sputum samples. | (DOCX)Click here for additional data file. | PMC10490889 | ||
Details on missing value imputation. | (DOCX)Click here for additional data file. | PMC10490889 | ||
Characteristics of the TREATS study participants population by arm, country, and overall totals. | (DOCX)Click here for additional data file. | PMC10490889 | ||
HIV indicators collected during TREATS by arm, country, and overall totals. | (DOCX)Click here for additional data file. | PMC10490889 | ||
Characteristics of participants with prevalent TB, by trial arm and country. | (DOCX)Click here for additional data file. | PMC10490889 | ||
TB prevalence by country, comparing individuals who self-reported they were HIV–positive and taking ART with HIV–negative individuals, overall and stratified by sex and age group. | (DOCX)Click here for additional data file. | PMC10490889 | ||
TB prevalence by trial arm, sensitivity analyses. | (DOCX)Click here for additional data file. | PMC10490889 | ||
CONSORT 2010 checklist of information to include when reporting a cluster-randomised trial. | Extension of CONSORT for abstracts to reports of cluster-randomised trials.(PDF)Click here for additional data file. | PMC10490889 | ||
Tuberculosis Reduction through Expanded Anti-Retroviral Treatment and Screening (TREATS) Project. | (PDF)Click here for additional data file. | PMC10490889 | ||
Statistical analysis plan. | FRANK | (PDF)Click here for additional data file.The authors would like to express their appreciation and gratitude to all members of the TREATS study team in Zambia and South Africa for their hard work in sometimes difficult circumstances. We also appreciate the participation, time, and information sharing of the study partic... | PMC10490889 | |
References | PMC10490889 | |||
Subject terms | depression, Depression, anxiety | RENAL | Renal replacement therapy is associated with reduced physical activity. The aim of the study was to assess the relationship between regular physical activity performed with the use of virtual reality and the occurrence of symptoms of anxiety and depression in hemodialysis patients. The study involved 85 patients from t... | PMC10394078 |
Introduction | anger, Anxiety, chronic kidney disease, anxiety, kidney disease, CKD, ESRD, psychiatric, depression, helplessChronic kidney disease, depressive disorders | NEUROLOGICAL DISEASE, KIDNEY DISEASE, CHRONIC DISEASES, DISORDERS, END-STAGE RENAL DISEASE, EVENTS, ESRD | Anxiety is one of the common psychiatric symptoms in patients with End-Stage Renal Disease (ESRD) treated with hemodialysis (HD). Apart from anxiety, depressive disorders also often appear. Symptoms of anxiety and depression occur in 50% of patients receiving renal replacement therapy using hemodialysis, and the freque... | PMC10394078 |
Materials and methods | chronic kidney disease, epilepsy, neurological or mental diseases, SD, visual disturbances, heart failure, End-Stage Renal Disease, diabetes | DISEASES, CARDIOVASCULAR DISEASES, EPILEPSY, SENILE DEMENTIA, MALIGNANT TUMORS, ARTERIAL HYPERTENSION, ACUTE CORONARY SYNDROME, HEART FAILURE, END-STAGE RENAL DISEASE, DISEASES, DIABETES | The research was performed from March 2021 to February 2022. 102 people with the fifth stage of chronic kidney disease, treated with renal replacement therapy by hemodialysis, were qualified for the study by a nephrologist. (Fig. Qualification scheme for the research.Ultimately, 85 patients treated with renal replaceme... | PMC10394078 |
Qualification scheme for the research | The examined patients were randomly divided into two groups: study group and control group depending on the assigned intervention. The study group consisted of patients undergoing renal replacement therapy by hemodialysis, whose task was to perform VR exercises using the prototype of the NefroVR system for 20 min durin... | PMC10394078 | ||
Description of the research performed in the study and control group | PMC10394078 | |||
Survey research | depression, Depression, Anxiety, low mood | At the time of entering the research, patients were asked to fill in a questionnaire prepared specifically for the study, containing demographic questions regarding the health condition and lifestyle of the participant.The respondents were asked to complete the following questionnaires: Beck Depression Inventory, Gener... | PMC10394078 | |
Statistical analysis | Statistical analysis was performed using the licensed program Statistica 13.0 (StatSoft, Inc. Tulsa, OK, USA). In order to characterize the group, descriptive statistics, means, standard deviations, medians, as well as multiplicities and percentages were used. The Shapiro–Wilk test was used to assess the normality of t... | PMC10394078 | ||
Institutional review board statement | The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of the Pomeranian Medical University (No. KB-0012/144/2020 of 5 October 2020). | PMC10394078 | ||
Informed consent statement | Informed consent was obtained from all subjects involved in the study. | PMC10394078 | ||
Discussion | CKD, chronic kidney disease, anxiety, chronic kidney diseaseCurrently, depression, Depression, trauma | Symptoms of anxiety and depression are common in patients treated with renal replacement therapy by hemodialysisThe studies by Zhang et al. (2014) showed that depression and anxiety were more common in the group of hemodialysis patients compared to the group of healthy personsThe literature describes many of the benefi... | PMC10394078 | |
Limitations | deaths, CKD, chronic kidney disease | This study has many limitations. Due to the COVID-19 pandemic, it was conducted in one dialysis center and a small number of participants was recruited.The results obtained were also affected by the deteriorating health of CKD patients, renal replacement therapy and the presence of various comorbidities. In the study o... | PMC10394078 | |
Author contributions | Conceptualization, A.T-S., H.M., N.T., A.R.,K.C., R.N., I.R.; methodology, A.R., A.T-S, R.N. ; soft-ware, R.N.,N.T.,A.T-S.; validation, I.R, K.C.; formal analysis, A.R., A.S., A.S-T., I.R.; investigation, M.M-M, N.T., A.R., A.S., H.M.; resources, R.N., K.C., I.R. ; data curation, A.R., A.S., R.N., K.C.; writing—origina... | PMC10394078 | ||
Funding | This research was funded by Regional program financed from European Funds RPZP.01.01.00-32-0010/19. | PMC10394078 | ||
Data availability | The pooled data that support the findings of this study are available from the first author, A.T-S., upon reasonable request. | PMC10394078 | ||
Competing interests | The authors declare no competing interests. | PMC10394078 | ||
References | PMC10394078 | |||
1. Introduction | obesity, inflammation, T2D, diabetes | OBESITY, LIPEMIA, CARDIOVASCULAR DISEASE, INFLAMMATION, TYPE 2 DIABETES, DISEASES, DIABETES | These authors contributed equally to this work.High glycemic response (GR) is part of cardiometabolic risk factors. Dietary polyphenols, starch digestibility, and dietary fibers could play a role in modulating GR. We formulated cereal products with high dietary fibers, polyphenols, and slowly digestible starch (SDS) co... | PMC10609865 |
2. Materials and Methods | PMC10609865 | |||
2.1. Test Products: Nutritional Composition and Starch Digestibility | CLC | PACS | Four wheat flour-based products were prepared using rotary molded biscuit technology and extrusion technology. Two sizes of biscuits were produced for both enriched and control products with large-size cookies (enriched larger cookies (ELC) or control larger cookies (CLC)) and mini biscuits (enriched mini biscuits (EMB... | PMC10609865 |
2.2. Nutritional Composition and Starch Digestibility Analyses | The nutritional composition of the cereal-based products was analyzed with the following methodologies: total dietary fibers: AOAC 2009.01; available starch: enzymatic method (as described in the French standard V18-121, 1997); sugars from DP1 to DP7: method by high-pressure ion chromatography (HPIC); fat: Randall meth... | PMC10609865 | ||
2.3. Human Participants and the In Vivo Study | iAUCg | Twelve healthy, non-smoking volunteers between 18 and 45 years old and with a body mass index (BMI) between 18.5 to 25 kg/mThe GI of a given food reflects how much its digestible carbohydrate content raises blood glucose levels. It is defined as the incremental area under the blood glucose response curve (iAUCg) after ... | PMC10609865 | |
2.4. Statistical Analysis | Descriptive statistics (mean, SD, SEM) of all measured and calculated (GI and II) variables related to each food were determined using JMPA repeated-measure analysis of variance (ANOVA) was used to evaluate the kinetics of glycemia and the insulinemia testing product, time as fixed effects, product × time interaction, ... | PMC10609865 | ||
3. Results | PMC10609865 | |||
3.1. Nutrition Composition and Starch Digestibility | The nutrition composition of the four cereal products (enriched and control) is provided in | PMC10609865 | ||
3.2. Glycemic and Insulinemic Responses | CLC | The kinetics of glycemia and insulinemia for the four products are presented as mean ± SEM in There was a significant product (GI and II showed differences between the products. Indeed, GI values of enriched products (ELC and EMB) were lower compared to the control products (CLC and CMB; | PMC10609865 | |
4. Discussion | inflammation | INFLAMMATION, OXIDATIVE STRESS | In this study we investigated the impact of complementary nutritional improvements (SDS, fibers, and polyphenols) of cereal-based food products on GI and II, to demonstrate how food composition and processes can improve post-prandial metabolic responses. Presently, enriched food products containing more than 33% of SDS... | PMC10609865 |
5. Conclusions | diabetes | METABOLIC DISTURBANCE, DIABETES | Globally, the nutritional improvements of the enriched products led to an improvement in postprandial glycemic and insulin responses in healthy subjects. This beneficial short-term effect may be based on complementary mechanistic effects on glucose metabolism by playing on carbohydrate digestibility:SDS, due to the lim... | PMC10609865 |
Author Contributions | S.V. and A.M. designed the study; A.D. made the food products; F.S.A. conducted the clinical trial; A.M. and F.S.A. did the statistical analysis; A.M., F.S.A., A.D., H.H.-R., P.S., J.-A.N. and S.V. analyzed the data; S.V., A.D., H.H.-R. drafted the first version of the manuscript. All authors have read and agreed to th... | PMC10609865 | ||
Institutional Review Board Statement | The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Human Research Ethics Committee of the University of Sydney (protocol code 2019/475 and date of approval: 8 August 2019). | PMC10609865 | ||
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. | PMC10609865 | ||
Data Availability Statement | Data presented in this study are available upon request to the corresponding author. The data are not publicly available. | PMC10609865 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC10609865 | ||
References | mini-biscuits, CLC | INS | Kinetics of the postprandial glycemic response and insulinemic response after the ingestion of the enriched larger cookies (ELC), control larger cookies (CLC), and enriched mini biscuits (EMB) and control mini biscuits (CMB). Details of the ingredients and food processing of the four cereal products.Nutrition compositi... | PMC10609865 |
Abstract | chronic kidney disease, IgAN, primary glomerular disease, hematuria, IgA, non-IgAN | REGRESSION, MAY, HEMATURIA, IMMUNOGLOBULIN A NEPHROPATHY | Xiachuan Qin and Linlin Xia contributed equally to this work.This study aimed to develop and validate a combined nomogram model based on superb microvascular imaging (SMI)-based deep learning (DL), radiomics characteristics, and clinical factors for noninvasive differentiation between immunoglobulin A nephropathy (IgAN... | PMC10591537 |
Keywords | PMC10591537 | |||
Introduction | CKD, chronic kidney disease, IgAN, renal failure, kidney diseases, primary glomerulonephritis, nephropathy | RENAL FAILURE, KIDNEY DISEASES, NEPHROPATHY | Immunoglobulin A (IgA) nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, accounting for more than 40% of all biopsies in China, and is the main cause of chronic kidney disease (CKD) and renal failure [The well-known advantages of ultrasound imaging, such as low cost, noninvasiveness, a... | PMC10591537 |
Materials and methods | PMC10591537 | |||
Patients | tumor, IgAN, primary glomerular disease, infection, non-IgAN, TG | RENAL, TUMOR, RECRUITMENT, MAY, INFECTION, SECONDARY GLOMERULAR DISEASE, URINARY TRACT OBSTRUCTION, REGRESSION, -11, RENAL ARTERY STENOSIS, AUTOIMMUNE DISEASE | This prospective research conformed to the guidelines of the Declaration of Helsinki and was approved by the Internal Review Committee (PJ2022-11-29). Written informed consent was obtained from each study participant.We continuously recruited 120 patients with primary glomerular disease confirmed by biopsy as research ... | PMC10591537 |
Ultrasonic examination | apnea | An experienced ultrasound physician (with 16 years of experience in renal ultrasound) performed image acquisition on the day before the patient underwent renal puncture using a Canon ultrasonic system Aplio 700 (Canon Medical Systems, Otawara, Japan) with a 3.5 MHz linear probe (i8C1) during fasting for more than 6 h a... | PMC10591537 | |
Radiomics feature extraction | The kidney region of interest on ultrasound was manually segmented using ITK software (version 3.8.0, The process of radiomics features selection consists of several steps. Firstly, features with an ICC > 0.75 in the training cohort were selected. Secondly, the Mann-Whitney | PMC10591537 | ||
Deep learning feature extraction | DECAY | Before input the images into the deep learning framework, a sonographer who was experienced in kidney ultrasound cropped all the images to contain the entire kidney mask area. The images with the largest ROI of the kidney were then cropped. The cropped kidney mask maintained the complete edge without exceeding the imag... | PMC10591537 | |
Establishment of clinical nomogram model for DL radiomics | In our study, several feature selection methods were utilized to select optimal features, including the ICC method, The flow chart of the combined nomogram model integrating deep learning radiomics. | PMC10591537 | ||
Statistical analysis | All statistical analyses were performed using SPSS (version 25.0; IBM Corp., Armonk, NY, USA) and Python 2.7 (Python Software Foundation, Beaverton, OR, USA). Quantitative data with normal distribution are expressed as mean ± standard deviation, while quantitative data with non-normal distribution are expressed as medi... | PMC10591537 | ||
Results | Patient and baseline characteristics are shown in Patients’ baseline clinical characteristics.MRA: main renal artery; RI: resistance index. | PMC10591537 | ||
Establishment of clinical predictors | IgAN | REGRESSION | Univariate analysis of the training cohort showed that the following 11 items were significantly associated with IgAN (The multivariate logistic regression model included univariate predictors associated with IgAN. Multivariate regression analysis showed that IgA (OR = 0.181, 95% CI = 0.084–0.279, | PMC10591537 |
Performance of radiomics model | A total of 3,384 ultrasonographic features were extracted from the ultrasound images. 1728 features were found to be significantly different between the two groups, through inter- and intra-observer analyses and the Mann-Whitney Spearman correlation coefficients were calculated for the eight selected features in Radiom... | PMC10591537 | ||
Performance of DL model | Using the siamese neural network, 4096 deep learning features were extracted from each patient’s images, which included traditional US images and SMI images. Feature selection pipeline was performed using the same steps as radiomics analysis, and the most significant deep learning features were selected. Ultimately, se... | PMC10591537 | ||
Performance of clinical combinatorial nomogram model for DL radiomics | hematuria, IgAN, IgA nephropathy, non-IgAN | HEMATURIA, IGA NEPHROPATHY | We developed a combined nomogram to noninvasively differentiate IgAN and non-IgAN. The nomogram model combines five features, including DL_model score, Rad_model score, IgA, and hematuria. Each feature contributed to the nomogram output score based on a specific coefficient, and the total score of each patient was then... | PMC10591537 |
Discussion | IgAN, non-IgAN, primary glomerular disease | RENAL FAILURE, THROMBOTIC MICROANGIOPATHY | IgAN is the most common primary glomerular disease worldwide and the main cause of renal failure, requiring renal replacement therapy [Thrombotic microangiopathy is common in IgAN [After multivariate analysis of clinical laboratory indicators, IgA and urine occult blood were independent predictors for distinguishing Ig... | PMC10591537 |
Acknowledgment | This study has been supported by the Hebin Intelligent Robots Co., LTD. | PMC10591537 | ||
Disclosure statement | No potential conflict of interest was reported by the author(s). | PMC10591537 | ||
Data availability statement | The study data may be provided by contacting the corresponding author | PMC10591537 | ||
References | PMC10591537 | |||
Subject terms | CRB-401 | RELAPSED/REFRACTORY MULTIPLE MYELOMA, REFRACTORY MULTIPLE MYELOMA | Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (This is a post hoc 18-month follow-up analysis of the CRB-401 trial, tes... | PMC10504071 |
Main | Multiple myeloma, tumor necrosis, MM | PLASMA CELL NEOPLASM, TUMOR NECROSIS, PROLIFERATION, MULTIPLE MYELOMA, REMISSION | Multiple myeloma (MM) is an incurable plasma cell neoplasm associated with substantial morbidity and mortality and generally shorter durations of response with each subsequent line of therapyAutologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to durable clinical remission in many patients with r... | PMC10504071 |
Results | PMC10504071 | |||
Secondary outcomes | The overall response rate (ORR) in all patients was 75.8%, with 64.5% achieving a very good partial response (VGPR) or better and 38.7% achieving a complete response (CR) or stringent CR (sCR; Fig. | PMC10504071 | ||
Efficacy outcomes in all dose groups. | Efficacy outcomes include the following: | PMC10504071 | ||
Exploratory outcomes | MINIMAL RESIDUAL DISEASE (MRD) | Responses were durable, with a median duration of response (DOR) in all patients of 10.3 months. The median DORs were 1.9 (95% confidence interval (CI), not estimable (NE)–NE) months, 13.7 (95% CI = 2.9–NE) months, 10.0 (95% CI = 6.3–14.8) months and 12.9 (20.9–NE) months in patients treated with 50, 150, 450 and 800 ×... | PMC10504071 | |
Correlates of durable response | tumor | DISEASE, MYELOMA, TUMOR | The concentration of BCMA in serum, a peripherally accessible and composite marker of change in myeloma tumor burden, was significantly greater in patients with myeloma who had progressive disease as best overall response compared with those achieving a response of PR or better to ide-cel, and changes in levels of circ... | PMC10504071 |
sBCMA dynamics and cellular kinetics associated with DOR. | Box and whisker plots are provided, whereby the center horizontal line denotes the median, and the box denotes the IQR (25th–75th percentiles). The upper whisker extends to the maximum value, but no further than 1.5× IQR above the 75th percentile, and the lower whisker extends to the minimum value, but no lower than 1.... | PMC10504071 | ||
Correlates of durable response | T CELL DYSFUNCTION | Thirteen of the 62 treated patients (21%) achieved a PFS interval of ≥18 months. These results were used to identify apheresis PBMC and DP correlates of long-term response to ide-cel. T cell phenotyping via standard flow cytometry was performed on both the PBMC starting material from apheresis and DP to evaluate T cell... | PMC10504071 | |
Correlates of long-term responders. | REGRESSION | Logistic regression analyses of starting material PBMC and final DP correlates from long-term responders (patients with PFS ≥ 18 months; Recent exposure to various prior antimyeloma therapies (hematopoietic stem cell transplantation (HSCT), alkylators, anti-CD38 antibody, corticosteroids, IMiDs and proteasome inhibitor... | PMC10504071 | |
Discussion | neurotoxicity, B-cell lymphoma, CRS | EVENTS, B-CELL LYMPHOMA | Patients with RRMM with triple-class exposure have poor outcomes and a high unmet need for new therapiesCRS and neurotoxicity are common events with CAR T cell treatments. In CRB-401, there were relatively few grade 3 CRS events (Based upon the totality of the efficacy and safety results during the dose escalation phas... | PMC10504071 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.